Printer Friendly

THE LIPOSOME COMPANY SUES VESTAR; SUIT CHARGES VESTAR'S AMBISOME INFRINGES LIPOSOME'S PATENT

 THE LIPOSOME COMPANY SUES VESTAR; SUIT CHARGES
 VESTAR'S AMBISOME INFRINGES LIPOSOME'S PATENT
 PRINCETON, N.J., June 23 /PRNewswire/ -- The Liposome Company, Inc. (NASDAQ: LIPO) today filed suit against Vestar, Inc. (NASDAQ: VSTR), in the United States District Court for the district of Delaware, alleging that Vestar is violating a patent assigned to the Liposome Company.
 The suit charges that the infringement is willful and deliberate, and calls for Vestar to pay the Liposome Company profits and damages resulting from the infringement, tripled, with interest.
 The patent that is the basis for the suit covers the dehydration of colloidal dispersions of liposomes. It is believed that Vestar's product AmBisome, which is being marketed in a number of countries, is in violation of this patent.
 "Based on what we have seen, we are confident in our position," said Dr. Allen Bloom, vice president and general counsel of the Liposome Company. "The published descriptions of Vestar's product leads us to believe that it is infringing our patent.
 "It is our policy to enforce our patents vigorously against all infringers. This policy applies to any parties that are now infringing any of our patents, or who do so in the future. We intend, at the appropriate time, to take any and all action necessary."
 A leading company dedicated exclusively to the development of liposome and lipid-based pharmaceuticals, the Liposome Company selectively develops proprietary parenteral pharmaceuticals for treatment, prevention and diagnosis of life-threatening illnesses.
 -0- 6/23/92
 /CONTACT: Anne M. Van Lent or Edward G. Silverman of the Liposome Company, 609-452-7060/
 (LIPO VSTR) CO: The Liposome Company, Inc.; Vestar, Inc. ST: New Jersey, California IN: MTC SU:


TQ-SM -- NY007 -- 2701 06/23/92 09:03 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 23, 1992
Words:282
Previous Article:XEROX ENGINEERING SYSTEMS ANNOUNCES HIGH-PERFORMANCE SYSTEM SOLUTION FOR ENGINEERING DOCUMENT MANAGEMENT
Next Article:RYKOFF-SEXTON BOARD DECLARES DIVIDEND
Topics:


Related Articles
VESTAR TO EXPAND PRODUCTION FACILITIES; SIGNS LEASE FOR 51,000-SQUARE-FOOT FACILITY
POTENTIAL NEW TREATMENT FOR LEISHMANIASIS TO ENTER HUMAN CLINICAL TRIALS
VESTAR FILES COUNTERCLAIM VS. THE LIPOSOME COMPANY: ALLEGES THAT PATENT IS INVALID AND DENIES INFRINGEMENT
VESTAR EXPRESSES CONFIDENCE IN PATENT POSITION; WILL VIGOROUSLY CONTEST ALL INFRINGEMENT ALLEGATIONS
VESTAR ISSUES STATEMENT REGARDING PATENT ISSUED TO LIPOSOME TECHNOLOGY, INC.
VESTAR FILES SUIT AGAINST LIPOSOME TECHNOLOGY, INC.
COURT FINDS VESTAR DOES NOT INFRINGE LTI PATENT
NEXAGEN AND VESTAR SIGN MERGER AGREEMENT
LIPOSOME TECHNOLOGY, INC. ANNOUNCES JUDGMENT
The Liposome Company and NeXstar Pharmaceuticals Settle Patent Litigation

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters